Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rayner

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Antimicrobial Agents and Chemotherapy|May 15, 2013
Population pharmacokinetics of oseltamivir: pediatrics through geriatricsMohamed A Kamal, Scott A Van Wart, Craig R Rayner, et al.
Clinical Pharmacology and Therapeutics|May 29, 2014
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approachM A Kamal, E P Acosta, D W Kimberlin, et al.
Bioorganic & Medicinal Chemistry|July 6, 2000
Cyclobutane carboxamide inhibitors of fungal melanin: biosynthesis and their evaluation as fungicidesL D Jennings, D R Rayner, D B Jordan, et al.
The Lancet. Global Health|April 18, 2021
How COVID-19 has fundamentally changed clinical research in global healthJay J H Park, Robin Mogg, Gerald E Smith, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2012
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studiesAgnès Poirier, Sara Belli, Christoph Funk, et al.
Nature|June 26, 1997
A family of cytokine-inducible inhibitors of signallingR Starr, T A Willson, E M Viney, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studiesC R Rayner, C C Bulik, M A Kamal, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
Infection and Drug Resistance|December 30, 2020
The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial RegistriesAlison Dillman, Michael J Zoratti, Jay J H Park, et al.
BMC Genomics|April 7, 2011
Deep sequencing analysis of the developing mouse brain reveals a novel microRNAKing-Hwa Ling, Peter J Brautigan, Christopher N Hahn, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Antimicrobial Agents and Chemotherapy|May 15, 2013
Population pharmacokinetics of oseltamivir: pediatrics through geriatricsMohamed A Kamal, Scott A Van Wart, Craig R Rayner, et al.
Clinical Pharmacology and Therapeutics|May 29, 2014
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approachM A Kamal, E P Acosta, D W Kimberlin, et al.
Bioorganic & Medicinal Chemistry|July 6, 2000
Cyclobutane carboxamide inhibitors of fungal melanin: biosynthesis and their evaluation as fungicidesL D Jennings, D R Rayner, D B Jordan, et al.
The Lancet. Global Health|April 18, 2021
How COVID-19 has fundamentally changed clinical research in global healthJay J H Park, Robin Mogg, Gerald E Smith, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2012
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studiesAgnès Poirier, Sara Belli, Christoph Funk, et al.
Nature|June 26, 1997
A family of cytokine-inducible inhibitors of signallingR Starr, T A Willson, E M Viney, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studiesC R Rayner, C C Bulik, M A Kamal, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
Infection and Drug Resistance|December 30, 2020
The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial RegistriesAlison Dillman, Michael J Zoratti, Jay J H Park, et al.
BMC Genomics|April 7, 2011
Deep sequencing analysis of the developing mouse brain reveals a novel microRNAKing-Hwa Ling, Peter J Brautigan, Christopher N Hahn, et al.
Pageof 15